SPARCL1 antibody
- Known as:
- SPARCL1 (anti-)
- Catalog number:
- orb43134
- Product Quantity:
- 50 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- SPARCL1 antibody
Related genes to: SPARCL1 antibody
- Gene:
- SPARCL1 NIH gene
- Name:
- SPARC like 1
- Previous symbol:
- -
- Synonyms:
- MAST9
- Chromosome:
- 4q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-09-17
- Date modifiied:
- 2016-10-05
Related products to: SPARCL1 antibody
Related articles to: SPARCL1 antibody
- Astrocytes regulate key aspects of the neural microenvironment that can be co-opted by cancer to support tumor growth and invasion. Secreted protein acidic and rich in cysteine-like 1 (SPARCL1) is a matricellular glycoprotein expressed by astrocytes and stromal cells, whose expression varies across cancer types. While SPARCL1 is downregulated in many peripheral cancers, reports of its expression in gliomas, specifically glioblastoma (GBM), are inconsistent. The biological context underlying these divergent findings, and the role of SPARCL1 in GBM malignancy, remains unclear. Publicly available transcriptomic datasets from the Ivy Glioblastoma Atlas Project (Ivy GAP), GlioVis, and TCGA were analyzed to evaluate SPARCL1 expression across GBM cohorts. Spatially resolved gene expression data from Ivy GAP were used to assess SPARCL1 expression from defined tumor regions. Microarray and RNA sequencing datasets from GlioVis and TCGA, respectively, were used to assess SPARCL1 expression across whole-tumor samples. Spatial transcriptomics from Ivy GAP show SPARCL1 expression was upregulated along the leading edge and in infiltrating tumor regions. Microarray datasets showed greater SPARCL1 expression in tumors of astrocyte lineage as opposed to oligodendrocyte lineage. Bulk RNA sequencing showed high SPARCL1 expression in low-grade gliomas, which is consistent with astrocytic lineage, IDH mutation, and spatial averaging effects that might obscure regional associations. These findings demonstrate that SPARCL1 expression in GBM is shaped by tumor architecture, molecular classification, and microenvironment interactions. Enrichment of SPARCl1 at invasive tumor margins is consistent with prior studies linking SPARCL1 to neuron-glioma synapse formation and angiogenesis. - Source: PubMed
Publication date: 2026/04/30
Allgood JuliAnne EJohnson TorrancePullan Jessica E - Astrocyte-derived extracellular matrix (ECM) proteins are critical for synaptic development and glutamatergic signaling, yet their role in attention deficit hyperactivity disorder (ADHD) remains poorly understood. This study examined serum levels of Thrombospondin-1 (Tsp-1), Sparc, and Sparcl-1 in children with ADHD and explored their associations with behavioral symptoms, executive dysfunction, and social impairments. Eighty-six children aged 6-12 years participated: 46 medication-naive with ADHD and 40 age- and sex-matched neurotypical controls. Clinical measures included the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L), Social Responsiveness Scale (SRS), and Behavior Rating Inventory of Executive Function (BRIEF). Serum levels of Tsp-1, Sparc, and Sparcl-1 were quantified via ELISA. Children with ADHD exhibited significantly lower serum levels of Tsp-1 (p < 0.001), Sparc (p = 0.020), and Sparcl-1 (p = 0.049) than controls. Lower Sparc levels were associated with poorer executive functioning and reduced social responsiveness, while lower Tsp-1 levels were positively associated with higher ADHD symptom severity. This study provides the first evidence of reduced serum astrocyte-derived ECM proteins in children with ADHD, implicating glia-mediated synaptic dysregulation in the disorder's pathophysiology. These findings suggest a novel glia-centered mechanism and support the potential of ECM proteins as biomarkers for ADHD subtypes and as targets for future therapeutic interventions. - Source: PubMed
Publication date: 2026/05/05
Kısmet Nilüfer YıldızGökçearslan Selen SezenÜlkar Serenay ElgünAçıkel Sadettin Burak - Secreted protein acidic and rich in cysteine-like 1 (SPARCL-1) is an extracellular matrix-associated matricellular protein involved in endothelial stability and vascular homeostasis. Given the central role of endothelial dysfunction in preeclampsia, we hypothesized that circulating SPARCL-1 levels would differ between early- and late-onset preeclampsia. Accordingly, this study aimed to evaluate maternal serum SPARCL-1 levels in women with early- and late-onset preeclampsia and to assess its diagnostic performance by disease onset. - Source: PubMed
Publication date: 2026/04/17
Shirinova SevinjÖzalp MiraçToplu Murat İbrahimAydoğdu Burak DenizMihmanlı Veli - The SPARC (secreted protein acidic and rich in cysteine) family represents a unique class of matricellular proteins - including SPARC, SPARCL1, SPOCK1-3, SMOC1-2, and FSTL1 - that regulate extracellular matrix (ECM) dynamics, cell signaling, and tissue homoeostasis. In cancer, their expression is frequently dysregulated, through epigenetic mechanisms, microRNAs, and interactions within the tumor microenvironment (TME). Dysregulation of SPARC family members is most pronounced in aggressive malignancies with SPARC, SPARCL1, SPOCK1, and SPOCK2 most consistently altered. These proteins drive tumor progression through ECM remodeling, epithelial-mesenchymal transition (EMT), maintenance of cancer stemness, immune modulation, and drug resistance acquisition. Their functions are highly context-dependent, exerting either tumor-suppressive or oncogenic effects depending on tissue types and disease stage. While their secreted nature positions family members as promising serum or plasma biomarkers, challenges such as ECM protein undruggability, functional heterogeneity, and the absence of upstream regulators have so far precluded direct therapeutic targeting, with no agents advancing to clinical trials. Nonetheless, indirect strategies leveraging their biology show preclinical promise. This review synthesizes current knowledge on SPARC family structure, regulation, and context-specific functions in cancer-TME interactions, emphasizing their dual roles as modulators of progression and resistance. By integrating mechanistic insights with translational advances, we highlight the emerging utility of SPARC family proteins in precision oncology and underscore the need for deeper understanding to enable effective biomarker development and targeted therapeutic strategies. - Source: PubMed
Publication date: 2026/04/14
Hoe Rachel Huey XuanRamasamy Thamil SelveeSinniah AjanthaAyob Ain Zubaidah - Joint use of multiple molecular layers can be useful to prioritize targets for mechanistic studies. Application of coronary disease in large populations is an emerging field. - Source: PubMed
Publication date: 2026/04/02
El-Sabawi BassimHuang XiaoningLin PhillipAnwar Mohammad YaserBetti MichaelKim NamjuPerry Andrew SPerera B Lakshitha AGajjar PriyaColangelo Laura AAmancherla KaushikSheng QuanhuZhao ShilinStolze LindsayFarber-Eger EricLandman Joshua MMiller Patricia ELiu Gabrielle YDas SumanWells Quinn STerry James GLloyd-Jones DonaldDas SaumyaKhan Sadiya SNorth Kari EBelow JenniferNayor MatthewKalhan RaviCarr John JeffreyGamazon Eric RShah Ravi V